Author

Jack Hirsh

Emeritus professor of medicine Mcmaster University Hamilton Ontario canada - Cited by 2,26,339 - Thrombosis andnhemostasis

Biography

Jack Hirsh is a medical scientist equally at home in the laboratory and the clinical setting. His many distinguished contributions to the field of thromboembolism, which combine basic research, patient management and clinical trials, underlie the therapy of thromboembolism worldwide.
Title
Cited by
Year
Heart disease and stroke statistics—2016 update: a report from the American Heart Association
D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ...circulation 133 (4), e38-e360, 201673717201
73717
2016
Medical device‐induced thrombosis: what causes it and how can we prevent it?
IH Jaffer, JC Fredenburgh, J Hirsh, JI WeitzJournal of Thrombosis and Haemostasis 13, S72-S81, 2015201
418
2015
Effect of short-term vs. long-term blood storage on mortality after transfusion
NM Heddle, RJ Cook, DM Arnold, Y Liu, R Barty, MA Crowther, ...New England Journal of Medicine 375 (20), 1937-1945, 2016201
309
2016
Laboratory monitoring of non–vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review
JW Eikelboom, DJ Quinlan, J Hirsh, SJ Connolly, JI WeitzJAMA cardiology 2 (5), 566-574, 2017201
132
2017
Real‐world variability in dabigatran levels in patients with atrial fibrillation
NC Chan, M Coppens, J Hirsh, JS Ginsberg, JI Weitz, T Vanassche, ...Journal of Thrombosis and Haemostasis 13 (3), 353-359, 2015201
76
2015
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials
T Vanassche, J Hirsh, JW Eikelboom, JS GinsbergThrombosis and haemostasis 112 (11), 918-923, 2014201
69
2014
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents
BJ Dale, JS Ginsberg, M Johnston, J Hirsh, JI Weitz, JW EikelboomJournal of Thrombosis and Haemostasis 12 (11), 1810-1815, 2014201
69
2014
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and …
NC Chan, JS Paikin, J Hirsh, MN Lauw, JW Eikelboom, JS GinsbergThrombosis and haemostasis 112 (05), 798-807, 2014201
64
2014
Peripheral oxygen saturation in older persons wearing nonmedical face masks in community settings
NC Chan, K Li, J HirshJAMA 324 (22), 2323-2324, 2020202
62
2020
Betrixaban (PRT054021): pharmacology, dose selection and clinical studies
NC Chan, J Hirsh, JS Ginsberg, JW EikelboomFuture Cardiology 10 (1), 43-52, 2014201
45
2014
A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal
NC Chan, D Siegal, MN Lauw, JS Ginsberg, JW Eikelboom, GH Guyatt, ...Journal of thrombosis and thrombolysis , 231-239, 2015201
40
2015
Role of phenotypic and genetic testing in managing clopidogrel therapy
NC Chan, JW Eikelboom, JS Ginsberg, MN Lauw, T Vanassche, JI Weitz, ...Blood, The Journal of the American Society of Hematology 124 (5), 689-699, 2014201
37
2014
Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials
NC Chan, AC Stehouwer, J Hirsh, JS Ginsberg, A Alazzoni, M Coppens, ...Thrombosis and haemostasis 114 (11), 1049-1057, 2015201
35
2015
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study
MH Ellis, T Neuman, H Bitterman, SG Dotan, A Hammerman, E Battat, ...European journal of internal medicine , 55-59, 2016201
33
2016
Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized …
JS Paikin, J Hirsh, JS Ginsberg, JI Weitz, NC Chan, RP Whitlock, G Pare, ...Journal of Thrombosis and Haemostasis 13 (3), 448-456, 2015201
32
2015
Apixaban-calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial
VC Bhagirath, JW Eikelboom, J Hirsh, M Coppens, J Ginsberg, ...TH Open 1 (02), e139-e145, 2017201
29
2017
The development and validation of an instrument to measure the quality of health research reports in the lay media
D Zeraatkar, M Obeda, JS Ginsberg, J HirshBMC public health 17 (1), 1-10, 2017201
26
2017
Reduction in mortality following elective major hip and knee surgery: a systematic review and meta-analysis
K Xu, NC Chan, Q Ibrahim, P Kruger, S Sinha, V Bhagirath, J Ginsberg, ...Thrombosis and Haemostasis 119 (04), 668-674, 2019201
25
2019
Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?—a systematic review
TAC de Vries, J Hirsh, K Xu, I Mallick, VC Bhagirath, JW Eikelboom, ...Thrombosis and Haemostasis 1 (09), 1323-1329,
20
2020
Fifty years of research on antithrombotic therapy: Achievements and disappointments
J Hirsh, JW Eikelboom, NC ChanEuropean Journal of Internal Medicine 70, 1-7, 191
20
2019

Referred From: https://scholar.google.com/citations?user=q5FEnFwAAAAJ&hl=en

Cited by
Citations 226339
h-index 175
i10-index 663
Recommended Journals
Open Access Journals